Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Neuronetics reported Q2 revenue of $41.6 million, up 9.1% year-over-year, driven primarily by a 16.8% increase in Greenbrook clinic revenue to $26.9 million. The company achieved a significant operational milestone, flipping Adjusted EBITDA to positive $0.3 million compared to a loss of $5.6 million in the prior year, while the net loss narrowed to $3.4 million. Neuronetics reaffirmed its full-year 2026 revenue guidance of $160 million to $164 million and tightened its operating expense outlook to a range of $95 million to $100 million.
Key figures
- Revenue
- 41600000
- Guidance
- FY2026 Total revenue $160M-$164M (vs prior $160M-$166M); Gross margin 48-50%; OpEx $95M-$100M
- Revenue Yoy
- 9.1%
- Gross margin
- 51.1%
- Net cash burn
- 1400000
- Neurostar revenue
- 14677000
- Greenbrook revenue
- 26900000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.